Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

Blood (2007) 110 (11): 256.

https://doi.org/10.1182/blood.V110.11.256.256

Published: 2007

Journal Articles

In Vivo Effects of Zoledronic Acid on Bone Remodeling.

Samantha Pozzi, MD, Teru Hideshima, MD, Sonia Vallet, MD, Siddhartha Mukherjee, MD, Shweta Chhetri, Diana Cirstea, MD, Nileshwari Vaghela, Clare Thomas, Dilani Rosa, Hiroshi Ikeda, MD, Yutaka Okawa, MD, Tanyel Kiziltepe, PhD, Jesse Schoonmaker, Ernestina Schipani, MD, Mary Bouxsein, PhD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2007) 110 (11): 3520.

https://doi.org/10.1182/blood.V110.11.3520.3520

Published: 2007

Journal Articles

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts

Blood (2007) 110 (10): 3744–3752.

https://doi.org/10.1182/blood-2007-05-093294

Published: 2007

Includes: Supplemental data

Journal Articles

CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells.

Sonia Vallet, MD, Noopur Raje, MD, Kenji Ishitsuka, MD, Teru Hideshima, MD, Klaus Podar, MD, Tanyel Kizeltepe, PHD, Hiroshi Yasui, MD, Shweta Chhetri, Enrique M. Ocio, MD, Janice Jin, Yutaka Okawa, MD, Hiroshi Ikeda, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3494.

https://doi.org/10.1182/blood.V108.11.3494.3494

Published: 2006

Journal Articles

Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00.

Noopur Raje, MD, Teru Hideshima, MD,PhD, Sonia Vallet, MD, Shweta Chhetri, Constantine Mitsiades, MD,PhD, Melissa Rooney, Hiroshi Yasui, Tanyel Kiziltepe, Klaus Podar, Yutaka Okawa, Hiroshi Ikeda, Dharminder Chauhan, Nikhil C. Munshi, Somesh Sharma, Himanshu Parikh, Bruce Chabner, Kenneth C. Anderson

Blood (2006) 108 (11): 3454.

https://doi.org/10.1182/blood.V108.11.3454.3454

Published: 2006

Journal Articles

BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma.

Hiroshi Yasui, MD, PhD, Teru Hideshima, M.D., Ph.D., Hiroshi Ikeda, M.D., Ph.D., Janice Jin, M.D., Enrique M. Ocio, D., Ph.D., Tanyel Kiziltepe, Ph.D, Yutaka Okawa, M.D., Ph.D., Sonia Vallet, M.D., Ph.D., Shweta Chhetri, Kenji Ishitsuka, M.D., Ph.D., Yu-Tzu Tai, Ph.D., Klaus Podar, M.D., Ph.D., Dharminder Chauhan, Ph.D., Chris Pargellis, Ph.D., Neil Moss, Ph.D., Noopur Raje, M.D., Ph.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 3440.

https://doi.org/10.1182/blood.V108.11.3440.3440

Published: 2006

Journal Articles

Clinical, Radiographic, and Biomarker Characterization of Multiple Myeloma Patients with Bisphosphonate Associated Osteonecrosis of the Jaw.

Noopur Raje, MD, Sook-Bin Woo, Karen Hande, Jeffrey T. Yap, Paul G. Richardson, MD, Sonia Vallet, Nathaniel Treister, Teru Hideshima, Yu-Tzu Tai, Shweta Chhetri, Brendan Connell, Agnieszka Szot-Barnes, Mei Tian, Robert L. Schlossman, Edie Weeler, Nikhil C. Munshi, Annick D. Van Den Abbeele, Kenneth C. Anderson

Blood (2006) 108 (11): 3591.

https://doi.org/10.1182/blood.V108.11.3591.3591

Published: 2006

Journal Articles

Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation towards Osteoblastic Lineage.

Siddhartha Mukherjee, MD, PhD, Noopur Raje, MD, Chirayu Patel, Sonia Vallet, MD, Joshua Aronson, Shweta Chhetri, Constantine Mitsiades, MD, Teru Hideshima, MD, PhD, Kenneth C. Anderson, MD, David T. Scadden, MD

Blood (2006) 108 (11): 88.

https://doi.org/10.1182/blood.V108.11.88.88

Published: 2006

Journal Articles

The In Vivo Activity of Neutralizing B Cell-Activating Factor (BAFF) Antibody in the Treatment of Multiple Myeloma (MM).

Paola Neri, MD, Shaji Kumar, MD, Mariateresa Fulciniti, MD, Sonia Vallet, MD, Shweta Chhetri, Hiroshi Yasui, Yu-Tzu Tai, PhD, Dharminder Chauhan, Teru Hideshima, Pierfrancesco Tassone, Salvatore Venuta, Nikhil C. Munshi, Kenneth C. Anderson, Noopur Raje

Blood (2006) 108 (11): 843.

https://doi.org/10.1182/blood.V108.11.843.843

Published: 2006

Journal Articles

Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/β-Catenin Pathway.

Hiroshi Yasui, MD, PhD, Teru Hideshima, M.D., Ph.D., Hiroshi Ikeda, M.D., Ph.D., Enrique M. Ocio, M.D., Ph.D., Tanyel Kiziltepe, Ph.D., Sonia Vallet, M.D., Ph.D., Yutaka Okawa, M.D., Ph.D., Shweta Chhetri, Kumar Sukhdeo, Kenji Ishitsuka, M.D., Ph.D., Klaus Podar, M.D., Ph.D., Noopur Raje, M.D., Ph.D., Dharminder Chauhan, Ph.D., Daniel R. Cattasco, M.D., Ph.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 5005.

https://doi.org/10.1182/blood.V108.11.5005.5005

Published: 2006

Journal Articles

Didox Induced Apoptosis Occurs by Inhibiting DNA Synthesis and Repair Via Down-Regulation of Ribonucleotide Reductase M1 in Multiple Myeloma (MM).

Noopur Raje, MD, Shaji Kumar, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Hiroshi Yasui, MD, PhD, Norihiko Shiraishi, PhD, Tanyel Kiziltepe, PhD, Shweta Chhetri, BS, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 5153.

https://doi.org/10.1182/blood.V106.11.5153.5153

Published: 2005

Journal Articles

The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).

Noopur Raje, MD, Shaji Kumar, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Hiroshi Yasui, MD, PhD, Yu-Tzu Tai, PhD, Norihiko Shiraishi, PhD, Tanyel Kizeltepe, PhD, Shweta Chhetri, BS, Sonia Vallet, MD, Robert L. Schlossman, MD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 3380.

https://doi.org/10.1182/blood.V106.11.3380.3380

Published: 2005

NARROW

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

In Vivo Effects of Zoledronic Acid on Bone Remodeling.

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts

CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells.

Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00.

BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma.

Clinical, Radiographic, and Biomarker Characterization of Multiple Myeloma Patients with Bisphosphonate Associated Osteonecrosis of the Jaw.

Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation towards Osteoblastic Lineage.

The In Vivo Activity of Neutralizing B Cell-Activating Factor (BAFF) Antibody in the Treatment of Multiple Myeloma (MM).

Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/β-Catenin Pathway.

Didox Induced Apoptosis Occurs by Inhibiting DNA Synthesis and Repair Via Down-Regulation of Ribonucleotide Reductase M1 in Multiple Myeloma (MM).

The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only